Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$5.15
+1.2%		$5.36
$2.03
▼
$7.18
$843.79M1.162.96 million shs2,094 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$55.32
+0.9%		$46.75
$14.78
▼
$55.81
$3.37B0.241.26 million shs168 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$27.79
$32.16
$21.14
▼
$42.21
$3.25B0.1932,963 shs956,633 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$9.89
$10.34
$6.28
▼
$14.27
$3.36B-0.31127,259 shs80,929 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
0.00%-2.49%-6.78%-11.48%+107.76%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
0.00%+3.51%+10.02%+31.44%+192.63%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%-6.24%-20.21%-2.25%+30.59%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%-3.23%-16.68%-12.17%-24.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$5.15
+1.2%		$5.36
$2.03
▼
$7.18
$843.79M1.162.96 million shs2,094 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$55.32
+0.9%		$46.75
$14.78
▼
$55.81
$3.37B0.241.26 million shs168 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$27.79
$32.16
$21.14
▼
$42.21
$3.25B0.1932,963 shs956,633 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$9.89
$10.34
$6.28
▼
$14.27
$3.36B-0.31127,259 shs80,929 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
0.00%-2.49%-6.78%-11.48%+107.76%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
0.00%+3.51%+10.02%+31.44%+192.63%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%-6.24%-20.21%-2.25%+30.59%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%-3.23%-16.68%-12.17%-24.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annexon, Inc. stock logo
ANNX
Annexon
2.20
Hold$15.33197.73% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.86
Moderate Buy$70.5027.44% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.93
Moderate Buy$49.4277.82% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.63
Moderate Buy$20.40106.27% Upside

Current Analyst Ratings Breakdown

Latest ANNX, TLX, NAMS, and ELVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Underperform
7/21/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Underperform$3.00
7/21/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$59.00 ➝ $67.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$58.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
7/20/2026
Annexon, Inc. stock logo
ANNX
Annexon
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/17/2026
Annexon, Inc. stock logo
ANNX
Annexon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$1.42 per shareN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$7.74 per shareN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M144.38N/AN/A$5.97 per share4.65
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.18$0.04 per share234.56$1.23 per share8.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A89.91N/AN/AN/AN/A8/20/2026 (Estimated)

Latest ANNX, TLX, NAMS, and ELVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/20/2026H1 2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$0.0434N/AN/AN/A$479.63 millionN/A
8/13/2026Q2 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.23N/AN/AN/A$6.50 millionN/A
8/12/2026Q2 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.3872N/AN/AN/AN/AN/A
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4726N/AN/AN/A$1.88 millionN/A
5/7/2026Q1 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A
5/7/2026Q1 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.44-$0.38+$0.06-$0.38N/AN/A
5/7/2026Q1 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annexon, Inc. stock logo
ANNX
Annexon
N/A
6.35
6.35
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
40.32
40.32
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.76
9.76
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.08
1.43
1.27

Institutional Ownership

CompanyInstitutional Ownership
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Annexon, Inc. stock logo
ANNX
Annexon
60163.84 million146.95 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5060.91 million59.08 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
4116.90 million102.01 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.78 millionN/AN/A

Recent News About These Companies

Health check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
August 3 at 1:29 AM  |  msn.comhttps://www.msn.com/en-au/money/markets/health-check-telix-jumps-first-hurdle-with-its-advanced-prostate-cancer-therapy-trial/ar-AA1XRZ52
CSL vs Telix shares: Which is the better buy?
August 3 at 1:29 AM  |  msn.comhttps://www.msn.com/en-au/money/top-stocks/csl-vs-telix-shares-which-is-the-better-buy/ar-AA29fFXI
Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat
July 31 at 10:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4928614-telix-pharmaceuticals-the-radiopharma-operating-system-is-the-real-moat
HC Wainwright Has Pessimistic Outlook of TLX FY2026 Earnings
July 31 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30931501
Telix H1 2026 Results: Investor Webcast Notification
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/telix-h1-2026-results-investor-223700467.html
Short Interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) Increases By 82.7%
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-telix-pharmaceuticals-limited-nasdaqtlx-increases-by-827-2026-07-30/
Equities Analysts Set Expectations for TLX FY2026 Earnings
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/equities-analysts-set-expectations-for-tlx-fy2026-earnings-2026-07-29/
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?
July 22, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2958171/does-telix-pharmaceuticals-limited-tlx-have-the-potential-to-rally-86-17-as-wall-street-analysts-expect?cid=cs-stocknewsapi-ft-tale_of_the_tape|consensus_price_target-2958171
Tuesday's HotCopper trends: Telix Pharma, Larvotto, Evion Group, and other daily topics
July 21, 2026  |  msn.comhttps://www.msn.com/en-au/money/news/tuesday-s-hotcopper-trends-telix-pharma-larvotto-evion-group-and-other-daily-topics/ar-AA28lvtC
Are Telix shares a buy, hold or sell following results?
July 21, 2026  |  fool.com.auhttps://www.fool.com.au/2026/07/22/are-telix-shares-a-buy-hold-or-sell-following-results/
Telix doses first patient in phase 3 renal cancer trial
July 21, 2026  |  msn.comhttps://www.msn.com/en-sg/money/other/telix-doses-first-patient-in-phase-3-renal-cancer-trial/ar-AA28myue
Up 79% since February, why are Telix shares jumping higher again on Tuesday?
July 21, 2026  |  fool.com.auhttps://www.fool.com.au/2026/07/21/up-79-since-february-why-are-telix-shares-jumping-higher-again-on-tuesday/
Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
July 21, 2026  |  fool.com.auhttps://www.fool.com.au/2026/07/21/telix-pharmaceuticals-q2-2026-revenue-jumps-21/
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330996/0/en/tlx591-tx-prostact-select-study-published-in-cancers-journal.html
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
July 20, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/telix-q2-revenue-us-247m-strong-momentum-and-pipeline-progress-1036343402
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3330166/0/en/telix-q2-revenue-us-247m-strong-momentum-and-pipeline-progress.html
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3330128/0/en/telix-doses-first-patient-in-phase-3-luteon-trial-of-tlx250-tx-for-renal-cancer.html
Telix Pharmaceuticals (NASDAQ:TLX) Downgraded by Royal Bank Of Canada to Sector Perform
July 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-downgraded-by-royal-bank-of-canada-to-sector-perform-2026-07-17/
Telix completes Japan phase 3 enrollment for Illuccix
July 17, 2026  |  msn.comhttps://www.msn.com/en-sg/money/general/telix-completes-japan-phase-3-enrollment-for-illuccix/ar-AA285WSH
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
July 17, 2026  |  aol.comA
Telix doses first patients in OPTIMAL e prostate cancer trial
July 16, 2026  |  msn.comhttps://www.msn.com/en-sg/news/other/telix-doses-first-patients-in-optimal-e-prostate-cancer-trial/ar-AA280QcB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Annexon stock logo

Annexon NASDAQ:ANNX

$5.15 +0.06 (+1.18%)
As of 08:27 AM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$55.32 +0.51 (+0.93%)
As of 08:59 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$27.79 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$27.76 -0.04 (-0.13%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$9.89 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$9.88 -0.01 (-0.10%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas